Table 2.
Base-case cost-effectiveness results from the Chinese healthcare perspective
| Cost, CNY | QALY | ICER, CNY | |||
|---|---|---|---|---|---|
| Total | Incremental | Total | Incremental | ||
| PEACE | |||||
| Statins | 299509.17 | NA | 8.19 | NA | NA |
| Statins + Evo 140mgQ2W | 348242.12 | 48732.96 | 8.54 | 0.35 | 137755.18 |
| Statins + Evo 420mgQM | 375490.01 | 75980.84 | 8.54 | 0.35 | 214777.76 |
| BERSONa | |||||
| Statins | 279123.88 | NA | 9.64 | NA | NA |
| Statins + Evo 140mgQ2W | 330152.91 | 51029.03 | 10.18 | 0.54 | 94869.54 |
| Statins + Evo 420mgQM | 365284.28 | 86160.40 | 10.13 | 0.49 | 177450.90 |
| SuValue®, LDL-C ≥ 100 mg/dl | |||||
| Statins | 300258.69 | NA | 8.33 | NA | NA |
| Statins + Evo 140mgQ2W | 324484.37 | 24225.68 | 8.92 | 0.59 | 40905.80 |
| Statins + Evo 420mgQM | 353686.48 | 53427.79 | 8.92 | 0.59 | 90214.47 |
| SuValue®, LDL-C ≥ 70 mg/dl | |||||
| Statins | 284482.16 | NA | 8.39 | NA | NA |
| Statins + Evo 140mgQ2W | 318921.61 | 34439.45 | 8.86 | 0.48 | 72449.95 |
| Statins + Evo 420mgQM | 347889.94 | 63407.78 | 8.86 | 0.48 | 133390.36 |
CNY, Chinese Yuan; Evo 140mgQ2W, evolocumab 140 mg every 2 weeks; Evo 420mgQM, evolocumab 420 mg monthly; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; NA, not applicable
a: The background statin in the BERSON study was atorvastatin 20 mg/d